Scarica l'app Stockscreener
0.5456
9.12%
0.0456
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Medicus Pharma CEO discusses promising Phase 2 SkinJect resultsICYMI - Proactive financial news
Medicus Pharma on Bloomberg World - The Journal News | lohud.com
Medicus Pharma Marks Nasdaq Anniversary with Opening Bell Ceremony - The Globe and Mail
Risk Report: Will Medicus Pharma Ltd outperform the market in YEAR2026 Update & High Accuracy Investment Signals - baoquankhu1.vn
Medicus Pharma receives FDA clearance to begin Phase 2b Teverelix study - MSN
Medicus Pharma reports phase 2 results for basal cell carcinoma therapy - MSN
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy - MyChesCo
Medicus Pharma to spotlight AI-driven drug development at Longwood Miami CEO Forum - Proactive financial news
Medicus Pharma to Showcase AI-Enabled Drug Development at Longwood Miami CEO Forum - National Today
Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum - TipRanks
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum - Weatherford Democrat
Medicus Pharma to Present Drug Development Programs at Roth Conference - MyChesCo
Medicus Pharma prices $7 million share offering - MSN
MDCX Maintains Buy Rating with Stable Price Target | MDCX Stock News - GuruFocus
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive financial news
Medicus Pharma provides additional Phase 2 data for SkinJect Cancer therapy - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma - TipRanks
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer - Proactive financial news
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset - The Manila Times
Aug Ideas: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture - The Globe and Mail
Medicus Pharma CEO discusses Phase 2 skin cancer resultsICYMI - Proactive financial news
Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch - MyChesCo
Medicus Pharma (MDCX) registers 1.12M shares; Yorkville bought 4.47M shares - Stock Titan
Medicus Pharma (MDCX) sells 4.47M shares to Yorkville and prepays part of debenture - Stock Titan
Aug Intraday: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestWeekly Profit Recap & Low Drawdown Trading Techniques - baoquankhu1.vn
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort - Sahm
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Southwest Times Record
Small caps: Medicus Pharma, BioHarvest Sciences, Bit Digital, Nextech3D.ai… - Proactive financial news
Small cap wrap: Medicus Pharma, BioHarvest Sciences, Bit Digital, Nextech3D.ai… - Proactive Investors
Medicus Pharma Ltd Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance And 40% Histological Clearance (CR) At Day 57 In 200µg Cohort - marketscreener.com
Medicus Pharma reports positive phase 2 results for microneedle skin cancer treatment - Proactive financial news
MDCX Navigates Uncertain Waters Amid Recent Earnings and Market Trends - timothysykes.com
Medicus Pharma Stock Swings After Skin Cancer Treatment Results - Benzinga
Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma - Yahoo Finance
Medicus Pharma Posts Strong Phase 2 Data for Microneedle Basal Cell Carcinoma Therapy - TipRanks
Microneedle skin cancer patch shows 73% clearance in Medicus trial - Stock Titan
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM - ACCESS Newswire
MDCXMedicus Pharma on Bloomberg World - mx.advfn.com
Medicus Pharma Showcases SkinJect and Teverelix Strategy at Roth Conference - TipRanks
Medicus Pharma to present at Roth Conference - Proactive financial news
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):